Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
| Condition | Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 |
|---|---|
| Phase | Phase 2 |
| Sponsor | National Cancer Institute (NCI) |
| Status | Active, not recruiting |
| Enrollment | 17 participants |
| Interventions | Berzosertib, Computed Tomography Assisted Biopsy, Endoscopic Biopsy, Irinotecan, Magnetic Resonance Imaging |
| Start date | Nov 16, 2020 |
| Completion date | Jul 1, 2024 |
| Results posted | Jul 8, 2025 |
Summary
This phase II trial studies the how well berzosertib and irinotecan work in treating patients with gastric or gastroesophageal junction cancer that is growing, spreading or getting worse (progressive), has spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Berzosertib may stop the growth of tumor cells by blocking some of the enzymes needed for growth. Chemotherapy drugs, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving berzosertib and irinotecan may work better than irinotecan alone in treating patients with gastric and gastroesophageal junction cancer.
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Response Criteria
| Treatment (Irinotecan and M6620) | 0 Participants |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Ad — Hoffmann-La Roche
- Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patient — National Cancer Institute (NCI)
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 — National Cancer Institute (NCI)
- Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Un — University of Southern California
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients — National Cancer Institute (NCI)
- Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poo — ECOG-ACRIN Cancer Research Group